Cited by 108Diet and metabolism studiesAlzheimer's disease research and treatmentsMitochondrial Function and Pathology

Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTg AD mouse model of Alzheimer's disease

Open access
Pawlosky, Robert J., Kemper, Martin F., Kashiwaya, Yoshihero, King, Michael Todd, Mattson, Mark P., Veech, Richard L.·2017·Journal of Neurochemistry

Abstract

In patients with Alzheimer's disease (AD) and in a triple transgenic (3xTg AD) mouse model of AD low glucose metabolism in the brain precedes loss of memory and cognitive decline. The metabolism of ketones in the brain by‐passes glycolysis and therefore may correct several deficiencies that are associated with glucose hypometabolism. A dietary supplement composed of an ester of D‐β‐hydroxybutyrate and R‐1,3 butane diol referred to as ketone ester (KE) was incorporated into a rodent diet and fed to 3xTg AD mice for 8 months. At 16.5 months of age animals were killed and brains dissected. Analyses were carried out on the hippocampus and frontal cortex for glycolytic and TCA (Tricarboxylic Acid) cycle intermediates, amino acids, oxidized lipids and proteins, and enzymes. There were higher concentrations of d‐β‐hydroxybutyrate in the hippocampus of KE‐fed mice where there were also higher concentrations of TCA cycle and glycolytic intermediates and the energy‐linked biomarker, N‐acetyl aspartate compared to controls. In the hippocampi of control‐fed animals the free mitochondrial [NAD+]/[NADH] ratio were highly oxidized, whereas, in KE‐fed animals the mitochondria were reduced. Also, the levels of oxidized protein and lipids were lower and the energy of ATP hydrolysis was greater compared to controls. 3xTg AD mice maintained on a KE‐supplemented diet had higher concentrations of glycolytic and TCA cycle metabolites, a more reduced mitochondrial redox potential, and lower amounts of oxidized lipids and proteins in their hippocampi compared to controls. The KE offers a potential therapy to counter fundamental metabolic deficits common to patients and transgenic models. image Read the Editorial Highlight for this article on page 162.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13958

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The ketone β-hydroxybutyrate raises NAD+ in neurons and suppresses Aβ and p-Tau pathologies and ameliorates behavioral deficits in a mouse model of AD.

    “the ketone β-hydroxybutyrate, which elevates NAD+ levels in neurons and has been shown to suppress Aβ and p-Tau pathologies and ameliorate behavioral deficits in a mouse model of AD”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Pawlosky et al., 2017

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pawlosky, R. J., Kemper, M. F., Kashiwaya, Y., King, M. T., Mattson, M. P., & Veech, R. L.
Affiliations
National Institutes of Health (US)
Corresponding author
Pawlosky, Robert J.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2017-03-15
Volume
141
Issue
2
Pages
195-207
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2576775595
Cited by
108
References
43
Citations by year
2026: 8 · 2025: 12 · 2024: 8 · 2023: 9 · 2022: 17 · 2021: 11 · 2020: 18 · 2019: 12 · 2018: 8 · 2017: 5
FWCI
8.70
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute on Aging
Topics
  • Health Sciences › Medicine › Physiology › Diet and metabolism studies
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
ketone esters, Alzheimer's disease, hippocampus, glycolysis, TCA cycle, D-β-hydroxybutyrate, N-acetylaspartate, mitochondrial redox potential, oxidative stress, oxidized lipids, oxidized proteins, brain glucose metabolism, dietary supplementation, ATP hydrolysis
MeSH terms
Alzheimer Disease, Amino Acids, Animals, Butanes, Citric Acid Cycle, Disease Models, Animal, Glycolysis, Hippocampus, Hydroxybutyrates, Ketone Bodies, Male, Mice, Inbred C57BL, Mice, Transgenic, Mice, Diet, Ketogenic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review